Table 3 Sensitivity and specificity of phenotypic ASTs and genotypic AMR predictions against the broth microdilution reference AST. Clinical breakpoints are applied as interpretive criteria for all ASTs
Antimicrobial | Sensitivity (95% CI) | Specificity (95% CI) | ||||
|---|---|---|---|---|---|---|
Disk diffusion | Agar dilution | Genotyping | Disk diffusion | Agar dilution | Genotyping | |
Ampicillin | 0.95 (0.85–0.99) | 0.95 (0.85–0.99) | 0.96 (0.88–1) | 1 (0.92–1) | 1 (0.92–1) | 0.93 (0.82–0.99) |
Chloramphenicol | 0.92 (0.8–0.98) | 0.71 (0.57–0.83) | 0.94 (0.83–0.99) | 0.98 (0.9–1) | 0.98 (0.9–1) | 0.94 (0.84–0.99) |
Gentamicin | 0.71 (0.29–0.96) | 0.86 (0.42–1) | 0 (0–0.41) | 1 (0.96–1) | 1 (0.96–1) | 1 (0.96–1) |
Nalidixic Acid | 0.82 (0.63–0.94) | 0.75 (0.55–0.89) | 0.82 (0.63–0.94) | 1 (0.95–1) | 0.96 (0.89–0.99) | 1 (0.95–1) |
Sulfamethoxazole | 0.97 (0.9–1) | 0.97 (0.9–1) | 0.67 (0.54–0.78) | 1 (0.89–1) | 0.94 (0.8–0.99) | 0.97 (0.84–1) |
Streptomycin | 0.96 (0.8–1) | 0.38 (0.2–0.59) | 0.92 (0.75–0.99) | 0.59 (0.47–0.7) | 1 (0.95–1) | 0.43 (0.32–0.55) |
Trimethoprim-Sulfamethoxazole | 1 (0.88–1) | 0.93 (0.78–0.99) | 0.97 (0.83–1) | 1 (0.95–1) | 0.97 (0.9–1) | 0.96 (0.88–0.99) |
Overall | 0.94 (0.9–0.96) | 0.83 (0.78–0.87) | 0.84 (0.79–0.88) | 0.93 (0.9–0.95) | 0.98 (0.97–0.99) | 0.88 (0.85–0.91) |